Giant-Cell Arteritis Market to Observe Stupendous Growth During the Forecast Period (2019-32) – Estimates DelveInsight | Key Companies – AbbVie, Regeneron, Novartis, IDEC Pharmaceuticals, and Others

Giant-Cell Arteritis Market to Observe Stupendous Growth During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - AbbVie, Regeneron, Novartis, IDEC Pharmaceuticals, and Others
Delveinsight Business Research LLP
As per DelveInsight, the Giant-Cell Arteritis Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.

DelveInsight’s “Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Giant-Cell Arteritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Giant-Cell Arteritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Giant-Cell Arteritis Market

Giant-Cell Arteritis: An Overview

According to the National Centre for Advancing Translational Sciences, “Giant-Cell Arteritis (GCA, also known as Temporal arteritis; Cranial Arteritis; Granulomatous Arteritis and Horton’s disease) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow”.

Giant-Cell Arteritis Market Key Facts

  • According to the data of the Arthritis Foundation, Caucasian women over the age of 50 (most commonly between the ages of 70 and 80 years), have the highest risk of developing Giant-Cell Arteritis. Although women are more likely than men to develop GCA, research suggests that men are more likely to suffer potentially blinding eye involvement.

  • The disease occurs most frequently in populations of Northern Europe, and in particular in Scandinavian countries where the incidence has been reported as high as 32.8 per 100,000 inhabitants over the age of 50 years.

  • According to the National Organization for Rare Diseases (NORD,), Giant-Cell Arteritis occurs in approximately 24 in 100,000 people over the age of 50 years, affecting twice as many females as males. Also, GCA affects 110,000 individuals in the United States.

Giant-Cell Arteritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Giant-Cell Arteritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Giant-Cell Arteritis market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Giant-Cell Arteritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Giant-Cell Arteritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant-Cell Arteritis market or expected to get launched during the study period. The analysis covers Giant-Cell Arteritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Giant-Cell Arteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Giant-Cell Arteritis Therapeutics Analysis

The dynamics of the Giant-Cell Arteritis market is anticipated to change in the coming years, owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. 

Some of the key companies in the Giant Cell Arteritis market include:

  • AbbVie

  • Regeneron Pharmaceuticals

  • Novartis Pharmaceuticals

  • IDEC Pharmaceuticals

And others.

Giant Cell Arteritis Therapies Covered in the report include:

  • Upadacitinib

  • Secukinumab

  • KEVZARA (sarilumab)

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Giant-Cell Arteritis Competitive Intelligence Analysis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Giant-Cell Arteritis Disease Background and Overview

6. Giant-Cell Arteritis Patient Journey

7. Giant-Cell Arteritis Epidemiology and Patient Population

8. Giant-Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Giant-Cell Arteritis Unmet Needs

10. Key Endpoints of Giant-Cell Arteritis Treatment

11. Giant-Cell Arteritis Marketed Products

12. Giant-Cell Arteritis Emerging Therapies

13. Giant-Cell Arteritis Seven Major Market Analysis

14. Attribute Analysis

15. Giant-Cell Arteritis Market Outlook (7 major markets)

16. Giant-Cell Arteritis Access and Reimbursement Overview

17. KOL Views on the Giant-Cell Arteritis Market.

18. Giant-Cell Arteritis Market Drivers

19. Giant-Cell Arteritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Chronic Periodontitis Market
“Chronic Periodontitis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Chronic Periodontitis Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States